U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT07452692) titled 'A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects' on Feb. 25.
Brief Summary: The two products used in this study are transdermal patches that contain selegiline. The test drug is the Selegiline Transdermal Delivery System (TDS). The comparator drug is the EMSAM(R) TDS.
The purpose of this research study is to compare how the skin tolerates the test TDS and the comparator TDS. The study will evaluate and compare skin irritation and possible allergic-type skin reactions (sensitization) caused by the two products.
The comparison will be based on how the skin responds to repeated applicatio...